Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Prodigiosin |
| Synonyms | |
| Therapy Description |
Prodigiosin is a small molecule that restores Tp53 function through activation of Tp73, resulting in tumor suppression (PMID: 24247721, PMID: 32754875). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Prodigiosin | p53 Activator 12 | Prodigiosin is a small molecule that restores Tp53 function through activation of Tp73, resulting in tumor suppression (PMID: 24247721, PMID: 32754875). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 mutant | colorectal cancer | sensitive | Prodigiosin | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 26759239). | 26759239 |
| TP53 wild-type | colorectal cancer | sensitive | Prodigiosin | Preclinical | Actionable | In a preclinical study, Prodigiosin inhibited self-renewal of Tp53 wild-type colorectal cancer cell lines in culture (PMID: 26759239). | 26759239 |
| TP53 loss | colorectal cancer | sensitive | Prodigiosin | Preclinical | Actionable | In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 loss in culture (PMID: 26759239). | 26759239 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|